Reasons to Retain STE Stock in Your Portfolio Now

Zacks12-18

STERIS plc’s STE growth in the fiscal second quarter of 2025 can be attributed to the robust performance of its Healthcare business. The company also benefits from the strong rebound prospects for its...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2492399969?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/_9OKqED6rOANF8VtUei37A--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/5d5a6eb884ce28277f39a4369974b5ea","is_english":true,"pubTime":"2024-12-18 00:48","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2492399969","market":"us","top_or_hot":-1,"title":"Reasons to Retain STE Stock in Your Portfolio Now","media":"Zacks","content":"<div>\n<p>STERIS plc’s STE growth in the fiscal second quarter of 2025 can be attributed to the robust performance of its Healthcare business. The company also benefits from the strong rebound prospects for its...</p>\n\n<a href=\"https://finance.yahoo.com/news/reasons-retain-ste-stock-portfolio-164800389.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Reasons to Retain STE Stock in Your Portfolio Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nReasons to Retain STE Stock in Your Portfolio Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-18 00:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/reasons-retain-ste-stock-portfolio-164800389.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>STERIS plc’s STE growth in the fiscal second quarter of 2025 can be attributed to the robust performance of its Healthcare business. The company also benefits from the strong rebound prospects for its...</p>\n\n<a href=\"https://finance.yahoo.com/news/reasons-retain-ste-stock-portfolio-164800389.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1169590202.USD","symbol_name":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","start_time":0,"source_url":"https://finance.yahoo.com/news/reasons-retain-ste-stock-portfolio-164800389.html","article_id":"2492399969","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/_9OKqED6rOANF8VtUei37A--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/5d5a6eb884ce28277f39a4369974b5ea"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492399969","pubTimestamp":1734454080,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"STERIS plc’s STE growth in the fiscal second quarter of 2025 can be attributed to the robust performance of its Healthcare business. The company also benefits from the strong rebound prospects for its Applied Sterilization Technologies  segment.Meanwhile, headwinds such as foreign currency risks and fierce competitive pressure are concerning.Year to date, shares of this Zacks Rank #3  company have lost 2.1% against the industry’s 7.6% growth and the S&P 500’s 18.4% increase.The renowned provider of infection prevention and other procedural products and services has a market capitalization of $21.15 billion. STE’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 1.18%.Strong Rebound Prospects in the AST Segment: This technology-neutral contract sterilization service successfully offers a wide range of sterilization modalities through a worldwide network of more than 50 contract sterilization and laboratory facilities. In the fiscal se","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","PEN":"Penumbra Inc","LU0106261612.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" ACC","BK4082":"医疗保健设备","IE00BLDYK493.USD":"NEUBERGER BERMAN US SMALL CAP \"A\" (USD) INC","IE0009354923.USD":"JANUS HENDERSON US VENTURE \"A2\" (USD) ACC","GMED":"Globus Medical Inc","BK4198":"医疗保健用品","BK4588":"碎股","LU0012050646.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" (USD) INC AV","IE00B64QTZ34.USD":"NEUBERGER BERMAN US SMALL CAP \"A\" (USD) ACC","HONE":"HarborOne Bancorp, Inc.","LU2065732104.USD":"ALLSPRING (LUX) WF GLOBAL SMALL CAP EQUITY \"I\" (USD) ACC","BK4548":"巴美列捷福持仓","LU0205193047.USD":"SCHRODER ISF US SMALL & MID-CAP EQUITY \"A\" (USD)  ACC","STE":"思泰瑞医疗","HAE":"美国血液技术","LU0205194284.USD":"SCHRODER ISF US SMALL & MID-CAP EQUITY \"A\" (USD) INC AV","LU1892829315.USD":"FIDELITY FUNDS SUSTAINABLE WATER & WASTE \"A\" (USD) ACC","BK4585":"ETF&股票定投概念"},"translate_title":"现在在您的投资组合中保留STE股票的理由","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"STE":1,"PEN":1,"GMED":1,"HAE":0.9,"HONE":0.9},"content_text":"STERIS plc’s STE growth in the fiscal second quarter of 2025 can be attributed to the robust performance of its Healthcare business. The company also benefits from the strong rebound prospects for its Applied Sterilization Technologies (“AST”) segment.\nMeanwhile, headwinds such as foreign currency risks and fierce competitive pressure are concerning.\nYear to date, shares of this Zacks Rank #3 (Hold) company have lost 2.1% against the industry’s 7.6% growth and the S&P 500’s 18.4% increase.\nThe renowned provider of infection prevention and other procedural products and services has a market capitalization of $21.15 billion. STE’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 1.18%.\nSTERIS: Key Upsides\nPromising Healthcare Business: The Healthcare segment is gaining from the successful market adoption of its comprehensive offerings, including infection prevention consumables and capital equipment. Further, its services to maintain that equipment, repair reusable procedural instruments and outsource instrument reprocessing services are gaining traction.\nFor the fiscal second quarter, Healthcare reported revenue growth of 9% year over year. This outperformance indicates a 12% improvement in consumable revenues and 14% growth in service revenues, driven by procedure volumes in the United States as well as price and market share gains. Healthcare achieved 7% constant currency organic revenue growth for the quarter. The success can be attributed to the actions of its operation team to reduce lead times and return backlog to normal levels. \nStrong Rebound Prospects in the AST Segment: This technology-neutral contract sterilization service successfully offers a wide range of sterilization modalities through a worldwide network of more than 50 contract sterilization and laboratory facilities. In the fiscal second quarter, the AST division experienced 9% reported growth year over year. This performance was driven by a 6% increase in service revenues and a significant improvement in capital equipment revenues. \nConstant currency organic revenues in the fiscal second quarter were in the high single digits. STERIS experienced its first signs of increased bioprocessing demand. Meanwhile, global MedTech customers were stable.\nSTERIS: Key Downsides\nForeign Currency Risks: With nearly 30% of the company’s revenues and cost of revenues being generated outside the United States, foreign currency exchange rate fluctuations can significantly affect its financial position, results of operations and competitive position. In the fiscal second quarter, revenues were negatively impacted by currency fluctuations of nearly $2.1 million.\nCompetitive Landscape: STERIS competes for pharmaceutical, research and industrial customers against several large companies with robust product portfolios and global reach, as well as several small companies with limited product offerings and operations in one or a few countries. STERIS’ Life Sciences segment operates in highly regulated environments where the most intense competition results from technological innovations, product performance, convenience and ease of use, and cost-effectiveness.  The company expects to continue to face competition in the future as new infection prevention, sterile processing, contamination control, gastrointestinal and surgical support products and services enter the market. \nImage Source: Zacks Investment Research\nEstimate Trends\nIn the past 30 days, the Zacks Consensus Estimate for STERIS’ fiscal 2025 earnings increased 0.9% to $9.10 per share.\nThe Zacks Consensus Estimate for fiscal 2025 revenues is pegged at $5.48 billion, which suggests 0.8% growth from the fiscal 2024 reported number.\nKey Picks\nSome better-ranked stocks in the broader medical space are Haemonetics HAE, Penumbra PEN and Globus Medical GMED.\nHaemonetics has an earnings yield of 5.02% compared with the industry’s 1.18%. Its earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 19.39%. HAE’s shares have risen 3.6% compared with the industry’s 19.9% growth in the past year.\nHAE carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.\nPenumbra, carrying a Zacks Rank #2 at present, has an estimated 2024 earnings growth rate of 33.5% compared with the industry’s 15.9%. Shares of Penumbra have risen 3.2% compared with the industry’s 14.5% growth in the past year. PEN’s earnings surpassed estimates in three of the trailing four quarters and missed in one, the average surprise being 10.54%.\nGlobus Medical, carrying a Zacks Rank #3 at present, has a long-term estimated growth rate of 14.1%. Shares of the company have rallied 81.8% compared with the industry’s 14.5% growth. GMED’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.65%.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nHaemonetics Corporation (HAE) : Free Stock Analysis Report\nSTERIS plc (STE) : Free Stock Analysis Report\nGlobus Medical, Inc. (GMED) : Free Stock Analysis Report\nPenumbra, Inc. (PEN) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2492399969"}